Business Wire

CA-KOMPANY

1.6.2016 15:22:25 CEST | Business Wire | Press release

Share
Tradeshift and kompany Announce Their Partnership to Automate Know-Your-Customer (KYC) and Know-Your-Business (KYB) Verifications Through Live Access to Authoritative Data from Commercial Registers Worldwide

In a global and networked marketplace, risk management is becoming crucial to businesses worldwide. The increase of compliance requirements, such as KYC, KYB, AML (anti-money-laundering), and EDD (enhanced due diligence), is driven both by regulatory changes and the commercial need to avoid business disruptions. Risk and procurement teams seek early detection of risks throughout the supply chain and require effective cloud-based tools.

kompany and Tradeshift have partnered to provide Tradeshift’s global customers with the tools and authoritative company data needed to reduce the time and costs associated with supplier verification. This will allow for up to 90% reduction in total costs and risk exposure compared to traditional services. As part of the cooperation, kompany will enable the Tradeshift platform via an app with real-time access to worldwide official commercial register data through its BREX (Business Register Exchange) API. “kompany and BREX will add tremendous value to trading partners on the Tradeshift platform with information to help them reduce fraud risks, collection costs, and third-party risks,” said Lars Krüger, Director Alliance Management, EMEA, Tradeshift.

In the future, kompany will also involve a company blockchain to offer one-stop-access to all available official information and documents on a company and its officers, including the identification and visualization of interconnections with other companies and beneficial owners worldwide. “Going forward, we are not only looking to provide a valid and complete picture of a company, but also want to harmonize the current jungle of company identifiers such as LEI, EUID, REID, DUNS® , Bloomberg Global ID/FIGI, Thomson Reuters PermID, EIN, VAT numbers, etc.” said Russell Perry , CEO and Co-Founder, kompany.

About kompany and BREX:

kompany ® provides real-time access to structured, official and authoritative commercial register data, including company filings covering more than 55 million companies in 80 jurisdictions. It also offers an Enterprise RESTful API called BREX.io to power third party business applications.

About Tradeshift:

Tradeshift is a global network and platform that connects buyers and suppliers. Tradeshift transforms the way companies buy, pay, and work with suppliers. They today connect 800,000 users across 190 countries.

Logos

kompany & BREX: https://www.kompany.com/pr/download-en/

Tradeshift: https://tradeshift.com/press/

Contact:

360kompany GmbH
Bernhard Hoetzl
Cell: +43 699 1376 4273
Email: bernhard.hoetzl@kompany.com

Link:

ClickThru

Social Media:

https://www.facebook.com/kompanycom

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release

New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu

Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release

Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co

SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release

The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release

Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye